The estimated Net Worth of Charles Conway is at least $3.65 Million dollars as of 6 January 2022. Charles Conway owns over 3,750 units of Biohaven Ltd stock worth over $854,958 and over the last 8 years he sold BHVN stock worth over $0. In addition, he makes $2,792,860 as Chief Scientific Officer at Biohaven Ltd.
Sign up
Charles Conway BHVN stock SEC Form 4 insiders trading
Charles has made over 6 trades of the Biohaven Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 3,750 units of BHVN stock worth $133,950 on 6 January 2022.
The largest trade he's ever made was exercising 13,885 units of Biohaven Ltd stock on 23 November 2021 worth over $393,779. On average, Charles trades about 2,853 units every 155 days since 2017. As of 6 January 2022 he still owns at least 23,935 units of Biohaven Ltd stock.
You can see the complete history of Charles Conway stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Conway biography
Dr. Charles Conway Ph.D. serves as Chief Scientific Officer of the Company., serves as Chief Scientific Officer of the Company. Dr. Conway has served as our chief scientific officer since January 2017. From January 2000 to January 2017, he held positions of increasing responsibility in drug discovery at BMS, most recently serving as associate director—biology analytics. Dr. Conway led BMS’s biology program efforts working on the CGRP antagonist program for over 10 years and was part of the full development team advancing rimegepant into clinical research. Dr. Conway has extensive experience in the field of pain research and is an inventor on three U.S. patents granted for the treatment of pain. Prior to his time at BMS, Dr. Conway was a postgraduate research anesthesiologist at the University of California San Diego. Dr. Conway received his B.S. in experimental psychology from the University of Central Missouri and his Ph.D. in neuroscience from the University of California Santa Barbara.
What is the salary of Charles Conway?
As the Chief Scientific Officer of Biohaven Ltd, the total compensation of Charles Conway at Biohaven Ltd is $2,792,860. There are 2 executives at Biohaven Ltd getting paid more, with Vlad Coric having the highest compensation of $6,787,630.
How old is Charles Conway?
Charles Conway is 58, he's been the Chief Scientific Officer of Biohaven Ltd since 2017. There are 5 older and 10 younger executives at Biohaven Ltd. The oldest executive at Biohaven Ltd is Julia Gregory, 67, who is the Independent Director.
What's Charles Conway's mailing address?
Charles's mailing address filed with the SEC is C/O BIOHAVEN PHARMACEUTICALS, INC., 215 CHURCH STREET, NEW HAVEN, CT, 06510.
Insiders trading at Biohaven Ltd
Over the last 8 years, insiders at Biohaven Ltd have traded over $8,186,598,135 worth of Biohaven Ltd stock and bought 8,852,002 units worth $137,738,037 . The most active insiders traders include Robert J Hugin, John W Childs, and Declan Doogan. On average, Biohaven Ltd executives and independent directors trade stock every 14 days with the average trade being worth of $2,840,776. The most recent stock trade was executed by John W Childs on 18 July 2024, trading 28,400 units of BHVN stock currently worth $1,013,028.
What does Biohaven Ltd's logo look like?
Complete history of Charles Conway stock trades at Biohaven Ltd
Biohaven Ltd executives and stock owners
Biohaven Ltd executives and other stock owners filed with the SEC include:
-
Vlad Coric,
Chief Executive Officer, Director -
William Jones,
Chief Commercial Officer, Migraine and Common Diseases -
Charles Conway,
Chief Scientific Officer -
Kimberly Gentile,
Senior Vice President - Clinical Operations -
James Engelhart,
Chief Financial Officer, Treasurer -
Elyse Stock,
Chief Medical Officer -
John Tilton,
Chief Commercial Officer, Rare and Orphan Diseases -
Dr. Vladimir Coric M.D.,
Chairman, CEO & Pres -
William Jones M.B.A.,
Chief Commercial Officer of Migraine & Common Diseases -
Julia Gregory,
Independent Director -
John Childs,
Director -
Gregory Bailey,
Director -
Dr. Elyse Stock M.D.,
Chief Medical Officer -
Kimberly Gentile,
Sr. VP of Clinical Operations -
Robert Berman,
Lead - Special Projects and Medical Oversight -
Robert Hugin,
Director -
Michael Heffernan,
Director -
Thomas Lynch,
Chairman of the Board -
Clifford Bechtold M.S.,
Pres & GM of Biohaven Ireland and Chief Compliance Officer -
Wendy Goss,
Exec. Admin. Assistant -
Dr. Charles Conway,
Chief Scientific Officer -
George C. Clark,
VP & Chief Accounting Officer -
Matthew DeLawder,
Director of Accounting -
Matthew Buten,
Chief Financial Officer -
Albert Cha,
Director -
Robert Repella,
Director -
Eric Aguiar,
-
Biotech Inc. Portage,
-
Declan Doogan,
-
Irina Antonijevic,
-
Kishan Mehta,
-
George C. Clark,
VP, Chief Accounting Officer -
Matthew Buten,
Chief Financial Officer -
Pharmaceutical Holding Co L...,
-
Bruce Car,
Chief Scientific Officer